{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:51:46Z","timestamp":1792270306482,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04517-x","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:46:59Z","timestamp":1738313219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Baricitinib represses the myocardial fibrosis via blocking JAK\/STAT and TGF-\u03b21 pathways in vivo and in vitro"],"prefix":"10.1186","volume":"25","author":[{"given":"Renlei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"4517_CR1","doi-asserted-by":"publisher","first-page":"926378","DOI":"10.3389\/fcvm.2022.926378","volume":"9","author":"L Zhu","year":"2022","unstructured":"Zhu L, Wang Y, Zhao S, Lu M. Detection of myocardial fibrosis: where we stand. Front Cardiovasc Med. 2022;9:926378.","journal-title":"Front Cardiovasc Med"},{"key":"4517_CR2","doi-asserted-by":"crossref","unstructured":"Graham C, Sethu P. Myocardial Fibrosis: Cell Signaling and In Vitro Modeling. In: Cardiovascular Signaling in Health and Disease. edn. Edited by Parinandi NL, Hund TJ. Cham (CH): Springer Copyright 2022, The Author(s). 2022: 287\u2013321.","DOI":"10.1007\/978-3-031-08309-9_10"},{"key":"4517_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.trsl.2019.03.001","volume":"209","author":"S Park","year":"2019","unstructured":"Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Translational Research: J Lab Clin Med. 2019;209:121\u201337.","journal-title":"Translational Research: J Lab Clin Med"},{"key":"4517_CR4","doi-asserted-by":"publisher","first-page":"1221881","DOI":"10.3389\/fphar.2023.1221881","volume":"14","author":"Z Ren","year":"2023","unstructured":"Ren Z, Zhang Z, Ling L, Liu X, Wang X. Drugs for treating myocardial fibrosis. Front Pharmacol. 2023;14:1221881.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4517_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41569-022-00799-2","volume":"20","author":"M Pesce","year":"2023","unstructured":"Pesce M, Duda GN, Forte G, Girao H, Raya A, Roca-Cusachs P, Sluijter JPG, Tsch\u00f6pe C, Van Linthout S. Cardiac fibroblasts and mechanosensation in heart development, health and disease. Nat Rev Cardiol. 2023;20(5):309\u201324.","journal-title":"Nat Rev Cardiol"},{"key":"4517_CR6","doi-asserted-by":"publisher","first-page":"1162754","DOI":"10.3389\/fendo.2023.1162754","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Wang Y, Yin R, Xu Y, Zhang L, Zhang Y, Yang L, Zhao D. Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy. Front Endocrinol (Lausanne). 2023;14:1162754.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"4517_CR7","doi-asserted-by":"publisher","first-page":"e10865","DOI":"10.15252\/emmm.201910865","volume":"12","author":"M Sweeney","year":"2020","unstructured":"Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol Med. 2020;12(10):e10865.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"4517_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/cells11091386","volume":"11","author":"H Venugopal","year":"2022","unstructured":"Venugopal H, Hanna A, Humeres C, Frangogiannis NG. Properties and functions of fibroblasts and myofibroblasts in myocardial infarction. Cells. 2022;11(9):1386.","journal-title":"Cells"},{"issue":"3","key":"4517_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11886-022-01647-y","volume":"24","author":"M Han","year":"2022","unstructured":"Han M, Zhou B. Role of cardiac fibroblasts in Cardiac Injury and Repair. Curr Cardiol Rep. 2022;24(3):295\u2013304.","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"4517_CR10","doi-asserted-by":"publisher","first-page":"e148554","DOI":"10.1172\/JCI148554","volume":"132","author":"JG Travers","year":"2022","unstructured":"Travers JG, Tharp CA, Rubino M, McKinsey TA. Therapeutic targets for cardiac fibrosis: from old school to next-gen. J Clin Invest. 2022;132(5):e148554.","journal-title":"J Clin Invest"},{"key":"4517_CR11","doi-asserted-by":"publisher","first-page":"115587","DOI":"10.1016\/j.bcp.2023.115587","volume":"213","author":"Q Pang","year":"2023","unstructured":"Pang Q, You L, Meng X, Li Y, Deng T, Li D, Zhu B. Regulation of the JAK\/STAT signaling pathway: the promising targets for cardiovascular disease. Biochem Pharmacol. 2023;213:115587.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4517_CR12","doi-asserted-by":"publisher","first-page":"e028623","DOI":"10.1161\/JAHA.122.028623","volume":"12","author":"SA Sabe","year":"2023","unstructured":"Sabe SA, Xu CM, Sabra M, Harris DD, Malhotra A, Aboulgheit A, Stanley M, Abid MR, Sellke FW. Canagliflozin improves myocardial perfusion, fibrosis, and function in a swine model of chronic myocardial ischemia. J Am Heart Assoc. 2023;12(1):e028623.","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"4517_CR13","doi-asserted-by":"publisher","first-page":"12571","DOI":"10.3390\/ijms241612571","volume":"24","author":"MP Adorni","year":"2023","unstructured":"Adorni MP, Papotti B, Borghi MO, Raschi E, Zimetti F, Bernini F, Meroni PL, Ronda N. Effect of the JAK\/STAT inhibitor tofacitinib on macrophage cholesterol metabolism. Int J Mol Sci. 2023;24(16):12571.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4517_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom13010119","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu J, Wang F, Luo F. The role of JAK\/STAT pathway in Fibrotic diseases: Molecular and Cellular mechanisms. Biomolecules. 2023;13(1):119.","journal-title":"Biomolecules"},{"key":"4517_CR15","doi-asserted-by":"publisher","first-page":"105414","DOI":"10.1016\/j.phrs.2020.105414","volume":"167","author":"R Singh","year":"2021","unstructured":"Singh R, Kaundal RK, Zhao B, Bouchareb R, Lebeche D. Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK\/STAT3 and JNK\/c-Jun signaling. Pharmacol Res. 2021;167:105414.","journal-title":"Pharmacol Res"},{"issue":"13","key":"4517_CR16","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.3390\/jcm12134527","volume":"12","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, De La Torre I, Richette P, Finckh A, Tanaka Y. A JAK inhibitor for treatment of rheumatoid arthritis: the Baricitinib experience. J Clin Med. 2023;12(13):4527.","journal-title":"J Clin Med"},{"issue":"4","key":"4517_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40257-023-00799-z","volume":"24","author":"S Fung","year":"2023","unstructured":"Fung S, Shirley M, Baricitinib. A review in severe Alopecia Areata. Am J Clin Dermatol. 2023;24(4):661\u201368.","journal-title":"Am J Clin Dermatol"},{"key":"4517_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2147\/JIR.S356316","volume":"15","author":"J Zhang","year":"2022","unstructured":"Zhang J, Qi F, Dong J, Tan Y, Gao L, Liu F. Application of Baricitinib in Dermatology. J Inflamm Res. 2022;15:1935\u201341.","journal-title":"J Inflamm Res"},{"key":"4517_CR19","doi-asserted-by":"publisher","first-page":"1217147","DOI":"10.3389\/fmed.2023.1217147","volume":"10","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos D, Parodis I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023;10:1217147.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4517_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42358-023-00305-3","volume":"63","author":"D Wang","year":"2023","unstructured":"Wang D, Wei Y, Xu L, Zhang J. Crosstalk between the JAK2 and TGF-\u03b21 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib. Adv Rheumatol (London England). 2023;63(1):22.","journal-title":"Adv Rheumatol (London England)"},{"issue":"5","key":"4517_CR21","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/molecules28052195","volume":"28","author":"S Gu","year":"2023","unstructured":"Gu S, Liang J, Zhang J, Liu Z, Miao Y, Wei Y, Li S, Gu J, Cui Y, Xiao T, Li X, Yang C. Baricitinib attenuates Bleomycin-Induced Pulmonary Fibrosis in mice by inhibiting TGF-\u03b21 signaling pathway. Molecules. 2023;28(5):2195.","journal-title":"Molecules"},{"key":"4517_CR22","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","volume":"9","author":"S Kubo","year":"2018","unstructured":"Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, Ishii A, Yamagata K, Nakano K, Tanaka Y. Janus kinase inhibitor Baricitinib modulates human innate and adaptive Immune System. Front Immunol. 2018;9:1510.","journal-title":"Front Immunol"},{"key":"4517_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fcvm.2019.00140","volume":"6","author":"A Hanna","year":"2019","unstructured":"Hanna A, Frangogiannis NG. The role of the TGF-\u03b2 superfamily in myocardial infarction. Front Cardiovasc Med. 2019;6:140.","journal-title":"Front Cardiovasc Med"},{"key":"4517_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yjmcc.2017.07.011","volume":"110","author":"Y Guo","year":"2017","unstructured":"Guo Y, Gupte M, Umbarkar P, Singh AP, Sui JY, Force T, Lal H. Entanglement of GSK-3\u03b2, \u03b2-catenin and TGF-\u03b21 signaling network to regulate myocardial fibrosis. J Mol Cell Cardiol. 2017;110:109\u201320.","journal-title":"J Mol Cell Cardiol"},{"key":"4517_CR25","doi-asserted-by":"publisher","first-page":"1125836","DOI":"10.3389\/fmed.2022.1125836","volume":"9","author":"Z Hou","year":"2022","unstructured":"Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, Wang H, Yang B, Liang Y, Ji S, Corrigendum. JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front Med (Lausanne). 2022;9:1125836.","journal-title":"Front Med (Lausanne)"},{"key":"4517_CR26","doi-asserted-by":"publisher","first-page":"109227","DOI":"10.1016\/j.biopha.2019.109227","volume":"118","author":"ZH Liu","year":"2019","unstructured":"Liu ZH, Zhang Y, Wang X, Fan XF, Zhang Y, Li X, Gong YS, Han LP. SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition. Biomed Pharmacother. 2019;118:109227.","journal-title":"Biomed Pharmacother"},{"key":"4517_CR27","doi-asserted-by":"publisher","first-page":"1092148","DOI":"10.3389\/fphar.2023.1092148","volume":"14","author":"C Li","year":"2023","unstructured":"Li C, Meng X, Wang L, Dai X. Mechanism of action of non-coding RNAs and traditional Chinese medicine in myocardial fibrosis: focus on the TGF-\u03b2\/Smad signaling pathway. Front Pharmacol. 2023;14:1092148.","journal-title":"Front Pharmacol"},{"key":"4517_CR28","doi-asserted-by":"crossref","unstructured":"Frangogiannis NG. TGF-\u03b2 as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities. Expert Opin Ther Targets. 2024;28(1-2):45-56.","DOI":"10.1080\/14728222.2024.2316735"},{"issue":"1","key":"4517_CR29","doi-asserted-by":"publisher","first-page":"a022137","DOI":"10.1101\/cshperspect.a022137","volume":"9","author":"K Luo","year":"2017","unstructured":"Luo K. Signaling Cross talk between TGF-\u03b2\/Smad and other Signaling pathways. Cold Spring Harb Perspect Biol. 2017;9(1):a022137.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"4517_CR30","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.2337\/diabetes.51.12.3505","volume":"51","author":"X Wang","year":"2002","unstructured":"Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak\/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes. 2002;51(12):3505\u20139.","journal-title":"Diabetes"},{"issue":"9","key":"4517_CR31","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1111\/jcmm.15175","volume":"24","author":"S Xu","year":"2020","unstructured":"Xu S, Mao Y, Wu J, Feng J, Li J, Wu L, Yu Q, Zhou Y, Zhang J, Chen J, Ji J, Chen K, Wang F, Dai W, Fan X, Guo C. TGF-\u03b2\/Smad and JAK\/STAT pathways are involved in the anti-fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis. J Cell Mol Med. 2020;24(9):5224\u201337.","journal-title":"J Cell Mol Med"},{"key":"4517_CR32","unstructured":"Wang HD, Lu DX, Huang QF. The role of JAK-STAT signaling pathway in cardiac remodeling. Progress in Physiological Sciences. 2003;34(4):365\u20138."},{"key":"4517_CR33","doi-asserted-by":"publisher","first-page":"108780","DOI":"10.1016\/j.biopha.2019.108780","volume":"113","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang L, Fan X, Yang W, Yu B, Kou J, Li F. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a\/\u03b2-catenin and Jak2\/Stat3 pathways. Biomed Pharmacother. 2019;113:108780.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"4517_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/01.CIR.0000057545.82749.FF","volume":"107","author":"EK Podewski","year":"2003","unstructured":"Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation. 2003;107(6):798\u2013802.","journal-title":"Circulation"},{"issue":"10349","key":"4517_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"RC Group","year":"2022","unstructured":"Group RC. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400(10349):359\u201368.","journal-title":"Lancet"},{"issue":"4","key":"4517_CR36","first-page":"339","volume":"59","author":"WW Brooks","year":"2009","unstructured":"Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med. 2009;59(4):339\u201343.","journal-title":"Comp Med"},{"issue":"1","key":"4517_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12872-022-02583-z","volume":"22","author":"T Lan","year":"2022","unstructured":"Lan T, Zeng Q, Jiang W, Liu T, Xu W, Yao P, Lu W. Metabolism disorder promotes isoproterenol-induced myocardial injury in mice with high temperature and high humidity and high-fat diet. BMC Cardiovasc Disord. 2022;22(1):133.","journal-title":"BMC Cardiovasc Disord"},{"key":"4517_CR38","doi-asserted-by":"publisher","first-page":"116000","DOI":"10.1016\/j.biopha.2023.116000","volume":"170","author":"L Qian","year":"2024","unstructured":"Qian L, Xu H, Yuan R, Yun W, Ma Y. Formononetin ameliorates isoproterenol induced cardiac fibrosis through improving mitochondrial dysfunction. Biomed Pharmacother. 2024;170:116000.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4517_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42358-023-00305-3","volume":"63","author":"D Wang","year":"2023","unstructured":"Wang D, Wei Y, Xu L, Zhang J. Crosstalk between the JAK2 and TGF-beta1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib. Adv Rheumatol (London England). 2023;63(1):22.","journal-title":"Adv Rheumatol (London England)"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04517-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04517-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:47:04Z","timestamp":1738313224000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04517-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4517"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04517-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal research was approved by the animal ethics committee of the Second Affiliated Hospital of Chongqing Medical University and performed according to our institute\u2019s guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}